Follicular lymphoma (FL) and germinal-centre B-cell like (GCB) diffuse large B-cell lymphoma (DLBCL) in particular were found to frequently harbour EZH2 gain-of-function mutations that renders them particularly sensitive to EZH2 inhibition. This evidence concerns the gene EZH2 and follicular lymphoma.